Could this Healthcare Stock really climb 1,029.03% by 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Prepare for the Next Wave of AI Stocks]( [Nvidia was just the beginning.]( [Click here to find out which three AI stocks I think have the most potential.]( --------------------------------------------------------------- November 17, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [AI "wealth window" will close January 9, 2024?]( Next-generation AI technology will create the first $100 TRILLION industry. AI 2.0 will open a brief “wealth window”… That will slam shut January 9, 2024. [>>HERE is everything you need now<<]( --------------------------------------------------------------- [Korro Bio]( Symbol: [KRRO]( Recent Price: $40.80 Average Analyst Price Target: $90.25 (121.20%) Market Cap: $334.85M Last Year's EPS: -$15.5 Consensus EPS Forecast: -$17.73 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Yasmeen Rahimi, analyst at Piper Sandler, reiterates coverage on [Korro Bio (KRRO)]( in the Healthcare sector with a Buy rating and a price target of $180 (6 days ago). [TipRanks.com]( also reports that [Korro Bio]( currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $90.25 . The target pricing ranges from a high forecast of $180 down to a low forecast of $0.5. [Korro Bio (KRRO)](’s last closing price was $40.80 which would put the average price target at 121.20% upside. Here are 3rd party ratings for [KRRO](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 22% (56 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [READ IMMEDIATELY: Huge banking overhaul underway]( The financial community has some big changes planned for your money. The Federal Reserve, US Treasury and White House are all involved... as are at least 41 American banks and credit unions. This overhaul could change how you cash your paycheck... access your social security income... even how you pay your taxes. That's why it's crucial you understand what's going on before your bank is affected. [Full story here.]( --------------------------------------------------------------- [Enanta Pharmaceuticals]( Symbol: [ENTA]( Recent Price: $8.69 Average Analyst Price Target: $19.60 (126.35%) Market Cap: $186.76M Last Year's EPS: -$1.79 Consensus EPS Forecast: -$2.38 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Ed Arce, analyst at H.C. Wainwright, reiterates coverage on [Enanta Pharmaceuticals (ENTA)]( in the Healthcare sector with a Buy rating and a price target of $30 (3 weeks ago). [TipRanks.com]( also reports that [Enanta Pharmaceuticals]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.60 . The target pricing ranges from a high forecast of $30 down to a low forecast of $14. [Enanta Pharmaceuticals (ENTA)](’s last closing price was $8.69 which would put the average price target at 126.35% upside. Here are 3rd party ratings for [ENTA](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Strong Sell, Top 30% (74 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Bioline RX Ltd Sponsored ADR]( Symbol: [BLRX]( Recent Price: $1.86 Average Analyst Price Target: $12.50 (1,029.03%) Market Cap: $104.72M Last Year's EPS: -$0.15 Consensus EPS Forecast: -$0.16 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Bioline RX Ltd Sponsored ADR (BLRX)]( in the Healthcare sector with a Buy rating and a price target of $21 (1 month ago). [TipRanks.com]( also reports that [Bioline RX Ltd Sponsored ADR]( currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $12.50 . The target pricing ranges from a high forecast of $4 down to a low forecast of $21. [Bioline RX Ltd Sponsored ADR (BLRX)](’s last closing price was $1.86 which would put the average price target at 1,029.03% upside. Here are 3rd party ratings for [BLRX](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Tech Insider: "ChatGPT's IPO - is this the final clue?"]( posted a strange legal promise to early investors on their website -- And what it says is truly shocking if you read between the lines. It’s why venture capitalist Luke Lango now believes an IPO announcement could happen at any moment. [Click here to see how to prepare.]( --------------------------------------------------------------- [Enlivex]( Symbol: [ENLV]( Recent Price: $1.74 Average Analyst Price Target: $12.00 (589.66%) Market Cap: $31.79M Last Year's EPS: -$0.39 Consensus EPS Forecast: -$0.43 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Enlivex (ENLV)]( in the Healthcare sector with a Buy rating and a price target of $12 (3 days ago). [TipRanks.com]( also reports that [Enlivex]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $12.00 . The target pricing ranges from a high forecast of $12 down to a low forecast of $12. [Enlivex (ENLV)](’s last closing price was $1.74 which would put the average price target at 589.66% upside. Here are 3rd party ratings for [ENLV](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Buy, Top 30% (74 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [BM Technologies]( Symbol: [BMTX]( Recent Price: $2.38 Average Analyst Price Target: $8.42 (157.56%) Market Cap: $28.49M Last Year's EPS: -$0.43 Consensus EPS Forecast: -$0.32 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Michael Diana, analyst at Maxim Group, reiterates coverage on [BM Technologies (BMTX)]( in the Technology sector with a Buy rating and a price target of $8 (2 months ago). [TipRanks.com]( also reports that [BM Technologies]( currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.42 . The target pricing ranges from a high forecast of $8 down to a low forecast of $13. [BM Technologies (BMTX)](’s last closing price was $2.38 which would put the average price target at 157.56% upside. Here are 3rd party ratings for [BMTX](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 45% (137 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Forget Tesla... Apple Car May Be The #1 EV Play]( Valley insider, Luke Lango, says his contacts are going crazy over Apple's latest project. Apple is preparing to upend the auto industry with their own EV... and this $5 stock could soar 40X once it goes live! [Click here to learn more.]( --------------------------------------------------------------- [ReNew Energy Global]( Symbol: [RNW]( Recent Price: $5.90 Average Analyst Price Target: $8.25 (48.81%) Market Cap: $2.24B Last Year's EPS: $0.19 Consensus EPS Forecast: $0.09 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Puneet Gulati, analyst at HSBC, reiterates coverage on [ReNew Energy Global (RNW)]( in the Utilities sector with a Buy rating and a price target of $8.75 (1 month ago). [TipRanks.com]( also reports that [ReNew Energy Global]( currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.25 . The target pricing ranges from a high forecast of $9 down to a low forecast of $7. [ReNew Energy Global (RNW)](’s last closing price was $5.90 which would put the average price target at 48.81% upside. Here are 3rd party ratings for [RNW](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 26% (64 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Agilent]( Symbol: [A]( Recent Price: $114.19 Average Analyst Price Target: $132.50 (4.80%) Market Cap: $32.66B Last Year's EPS: $1.27 Consensus EPS Forecast: $1.37 Expected Earnings Date: Nov 20 2023 Recent Analyst Action: Neil Beveridge, analyst at Bernstein, reiterates coverage on [Agilent (A)]( in the Healthcare sector with a Sell rating (1 week ago). [TipRanks.com]( also reports that [Agilent]( currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $132.50 . The target pricing ranges from a high forecast of $150 down to a low forecast of $105. [Agilent (A)](’s last closing price was $114.19 which would put the average price target at 4.80% upside. Here are 3rd party ratings for [A](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 35% (88 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketMoverAlerts.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. [If you are not a human, click here.]( By opening and/or clicking on any link contained within this email, you are reconfirming your opt-in status. You can unsubsubscribe at any time by clicking on the link in the footer. MarketMoverAlerts.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software